218 related articles for article (PubMed ID: 23206324)
1. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.
Hong J; Novick D; Brugnoli R; Karagianis J; Dossenbach M; Haro JM
BMC Psychiatry; 2012 Dec; 12():218. PubMed ID: 23206324
[TBL] [Abstract][Full Text] [Related]
2. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Haro JM; Novick D; Suarez D; Roca M
J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
[TBL] [Abstract][Full Text] [Related]
4. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
5. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
Curr Med Res Opin; 2008 May; 24(5):1399-405. PubMed ID: 18397549
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
7. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
9. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
[TBL] [Abstract][Full Text] [Related]
11. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
12. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
13. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.
Lee CT; Conde BJ; Mazlan M; Visanuyothin T; Wang A; Wong MM; Walker DJ; Roychowdhury SM; Wang H; Tran PV
J Clin Psychiatry; 2002 Jul; 63(7):569-76. PubMed ID: 12143912
[TBL] [Abstract][Full Text] [Related]
14. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
15. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.
Noordsy DL; Glynn SM; Sugar CA; O'Keefe CD; Marder SR
J Psychiatr Res; 2017 Dec; 95():299-307. PubMed ID: 28942217
[TBL] [Abstract][Full Text] [Related]
16. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
[TBL] [Abstract][Full Text] [Related]
17. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
[TBL] [Abstract][Full Text] [Related]
18. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
19. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study.
Novick D; Haro JM; Suarez D; Marques-Teixeira J; Naber D
Int Clin Psychopharmacol; 2008 Jul; 23(4):203-8. PubMed ID: 18545058
[TBL] [Abstract][Full Text] [Related]
20. [Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].
Meder J; Debowska G; Lis J; Araszkiewicz A; Sierosławska K; Kolesaric A; Treuer T
Psychiatr Pol; 2004; 38(3):469-84. PubMed ID: 15199656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]